HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

LY 2275796

an eIF-4E antisense oligonucleotide in phase I clinical trials (2011) for treatment of cancer

Also Known As:

ISIS 183750; LY-2275796; LY2275796

Networked: 2 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Nucleic Acids, Nucleotides, and Nucleosides: 1
- Nucleotides: 15763
  - Polynucleotides: 218
    - Oligonucleotides: 5145
      - LY 2275796: 2

Experts

1.	Abdullah, S: 1 article (10/2016)
2.	Abi-Jaoudeh, N: 1 article (10/2016)
3.	Anderson, V: 1 article (10/2016)
4.	Duffy, A G: 1 article (10/2016)
5.	Figg, W D: 1 article (10/2016)
6.	Fioravanti, S: 1 article (10/2016)
7.	Greten, T F: 1 article (10/2016)
8.	Lee, S: 1 article (10/2016)
9.	Levy, E: 1 article (10/2016)
10.	MacLeod, A R: 1 article (10/2016)

Related Diseases

1.

Neoplasms (Cancer)

10/15/2011 - "This phase I study sought an appropriate LY2275796 dose in patients with advanced tumors. "
10/01/2016 - "In tumor tissue, the intracellular and stromal presence of ISIS 183750 was detected by IHC in all biopsied patients. "
10/15/2011 - "LY2275796 was well tolerated up to 1,000 mg. Because tumor eIF-4E expression was decreased, but no tumor response observed, LY2275796 should be studied combined with other treatment modalities."
10/15/2011 - "A phase 1 dose escalation, pharmacokinetic, and pharmacodynamic evaluation of eIF-4E antisense oligonucleotide LY2275796 in patients with advanced cancer."
10/15/2011 - "Plasma samples were collected to determine LY2275796 concentrations and tumor biopsies to quantify eIF-4E mRNA/protein. "

Related Drugs and Biologics

1.	Eukaryotic Initiation Factor-4E
2.	RNA Cap-Binding Proteins (Cap Binding Protein)
3.	Antisense Oligonucleotides
4.	Messenger RNA (mRNA)
5.	Proteins (Proteins, Gene)